Form 4: Immunovant Chief Technology Officer Sells Shares to Cover Tax Obligations

Immunovant's Chief Technology Officer, Jay S. Stout, sold 2,195 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Summary

• Jay S. Stout, the Chief Technology Officer of Immunovant, Inc., sold 2,195 shares of common stock on January 22, 2025.
• The sale was executed at a price of $23.59 per share.
• This transaction was not a discretionary sale but was mandated by the company to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• The RSUs were part of a grant of 100,000 RSUs awarded on April 17, 2023, with 6,250 vesting on January 17, 2025.
• Following the transaction, Mr. Stout directly owns 139,991 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: This is a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for companies to require 'sell to cover' transactions to manage tax obligations.

Comparison to Industry Standards

• Many biotechnology companies use restricted stock units as part of their compensation packages.
• It is standard practice for executives to sell shares to cover tax obligations upon vesting of RSUs.
• The 'sell to cover' mechanism is a common method to manage tax liabilities associated with equity compensation.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
• The sale does not indicate any change in the executive's confidence in the company.

Key Dates

Keywords

Immunovant, stock sale, Form 4, restricted stock units, tax obligations, insider trading, executive compensation, IMVT